Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956489 | 0.83 | HCRTR1 (0.64) | HCRTR1HCRTR2 | |
| SCHEMBL17539230 | 0.83 | HCRTR2 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL17539260 | 0.83 | HCRTR2 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL8209215 | 0.82 | HCRTR2 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL14843881 | 0.80 | HCRTR2 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL13703423 | 0.80 | HCRTR2 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL2905303 | 0.80 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL13789995 | 0.80 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL2904616 | 0.80 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL21612202 | 0.79 | HCRTR2 (0.47) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2214676-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.